Study Assessing CLENPIQ As Bowel Preparation for Pediatric Colonoscopy

Launched by FERRING PHARMACEUTICALS · Oct 1, 2019

Keywords

ClinConnect Summary

This clinical trial is looking at a medication called CLENPIQ to see if it is effective for preparing children for a procedure called colonoscopy, which is done to examine the inside of the colon. The trial is currently recruiting participants who are between the ages of 2 and 8 years old and weigh at least 10 kilograms (about 22 pounds). To be eligible, children need to have regular bowel movements, averaging three or more per week for at least a month before the colonoscopy. Parents or guardians will need to provide consent for their child to participate.

If a child joins this trial, they will receive the CLENPIQ medication to help prepare their bowels before the colonoscopy. However, there are specific health conditions that would prevent participation, such as serious liver or kidney issues, recent surgery on the abdomen, or a history of certain gastrointestinal problems. It’s important for families to discuss any medical history with their healthcare provider to determine if their child is a good candidate for this study. Overall, this trial aims to make the bowel preparation process easier for young patients undergoing colonoscopies.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female, aged 2 years to \<9 years being scheduled to undergo elective colonoscopy.
• • Weight ≥10 kg (≥22 lbs).
• • Participants must have had an average of three or more spontaneous bowel movements (SBM) per week for 1 month prior to the colonoscopy.
• • Written informed consent (by parent(s)/ caregiver(s)/ guardian(s)) and assent (if applicable) obtained at screening.
• Exclusion Criteria:
• • History of significant liver, cardiovascular, or renal disease (including recent or ongoing oliguria).
• • Acute surgical abdominal conditions (e.g., acute obstruction or perforation) during the screening period.
• • Clinically significant abdominal pain during the screening period.
• • Severe acute inflammatory bowel disease (IBD) during the screening period.
• • Any prior colorectal surgery, excluding appendectomy and polyp removal.
• • History of colon disease (e.g., Hirschsprung disease, volvulus, idiopathic pseudo-obstruction, or hypomotility syndrome).
• • History of or ongoing intestinal ulceration, toxic megacolon or other toxic colitis.
• • History of upper gastrointestinal disorder (e.g., active ulcer, pyloric stenosis or other cause of gastric retention, gastroparesis, or ileus).
• • History of upper gastrointestinal surgery (e.g., gastric resection or gastric bypass), excluding cholecystectomy.
• • Chronic or persistent, severe nausea or vomiting during the screening period.
• • Moderate to severe dehydration during the screening period.
• • Prior history of epileptic reaction, convulsions, or seizures.
• • Any clinically relevant neurological events with or without association with hyponatremia during the screening period.
• • Serum creatinine, estimated glomerular filtration rate (eGFR), potassium, or sodium outside normal limits during the screening period.
• • Hypermagnesemia during the screening period.
• • Use of the following prohibited medication: lithium (within 48 hours prior to procedure), laxatives (within 24 hours prior to procedure), drugs that in the opinion of the investigator are causing constipation in the participant (within 48 hours prior to procedure), antidiarrheal drugs (within 72 hours prior to procedure), or oral iron preparations (within 1 week prior to procedure).
• • Participation in an interventional investigational trial requiring administration of an investigational drug within 30 days prior to receiving trial medication (or within 60 days for investigational drugs with an elimination half-life \>15 days).
• • Any clinically relevant abnormal findings in medical history, physical examination, vital signs, electrocardiogram (ECG), clinical chemistry, hematology, coagulation, or urinalysis at screening which in the opinion of the investigator(s), might put the participant at risk because of his/her participation in the trial.
• • Hypersensitivity to any of the ingredients of the trial medications.
• • Inability to comply with the dietary restrictions in the trial or the fluid requirements before and after investigational medicinal product (IMP) administration.